Tempus AI isn't an AI story.
It's a data moat story.
5,000+ U.S. institutions. One of the largest multimodal genomic databases in oncology. Years of proprietary clinical data that would be extraordinarily expensive and time-consuming to replicate.
Q1 2026: revenue +36% YoY. Data & Licensing revenue +69%. Net revenue retention: 126%.
Pharma clients aren't just renewing. They're expanding.
The market still appears to value Tempus closer to a diagnostics company than a data platform.
Yet the software and data business embedded inside it looks very different from traditional diagnostics.
Management is guiding for ~$65M adjusted EBITDA in 2026.
The key question isn't growth anymore.
It's operating leverage.
Reimbursement risk is real. Dilution risk is real.
But if the data asset continues compounding the way NRR suggests, the multiple investors assign to the business could look very different five years from now.
#AI #Genomics #Biotech $TEM
CapitMonet / Capitium Monetra
npub15q…n43pr
2026-06-04 18:32:07 UTC
Author Public Key
npub15qydznwe6gl3j57qusn0x8tum2fxlgkyt30udrpz6tctngr22zkqvn43prPublished at
2026-06-04 18:32:07 UTCEvent JSON
{
"id": "e07cb86be303062869e2e8a22c3d06241c619adc1d59f4f143e7f622d7aea20f",
"pubkey": "a008d14dd9d23f1953c0e426f31d7cda926fa2c45c5fc68c22d2f0b9a06a50ac",
"created_at": 1780597927,
"kind": 1,
"tags": [
[
"alt",
"A short note: Tempus AI isn't an AI story.\n\nIt's a data moat sto..."
],
[
"t",
"AI"
],
[
"t",
"ai"
],
[
"t",
"Genomics"
],
[
"t",
"genomics"
],
[
"t",
"Biotech"
],
[
"t",
"biotech"
],
[
"client",
"Amethyst"
]
],
"content": "Tempus AI isn't an AI story.\n\nIt's a data moat story.\n\n5,000+ U.S. institutions. One of the largest multimodal genomic databases in oncology. Years of proprietary clinical data that would be extraordinarily expensive and time-consuming to replicate.\n\nQ1 2026: revenue +36% YoY. Data \u0026 Licensing revenue +69%. Net revenue retention: 126%.\n\nPharma clients aren't just renewing. They're expanding.\n\nThe market still appears to value Tempus closer to a diagnostics company than a data platform.\n\nYet the software and data business embedded inside it looks very different from traditional diagnostics.\n\nManagement is guiding for ~$65M adjusted EBITDA in 2026.\n\nThe key question isn't growth anymore.\n\nIt's operating leverage.\n\nReimbursement risk is real. Dilution risk is real.\n\nBut if the data asset continues compounding the way NRR suggests, the multiple investors assign to the business could look very different five years from now.\n\n#AI #Genomics #Biotech $TEM",
"sig": "5ac7accd370e7c831e18b60b958aa6fd5ff957bcaa8534bdd233d25cd24ccdcb0c505780f1e0e2e6cdd7528f54ac0d47826a71c785e0ea5d998e5d5b200d0d28"
}